Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00082394 · ClinicalTrials.gov registry record · Phase 4
A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
NCT00082394 is a Phase 4 study that has completed, run by GlaxoSmithKline.
The verdict
NCT00082394, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
Study Summary
The aim of this study was to assess whether TRIZIVIR, administered twice-daily was as safe, tolerable and efficacious as a combination of the drugs COMBIVIR administered twice-daily and atazanavir administered once daily. Over the course of 48 weeks, various parameters that measure safety, tolerability and efficacy of the investigational drugs were measured and compared.
Interventions
- DRUG atazanavir
- DRUG Combivir
- DRUG Trizivir
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-04-26 |
| Est. Completion | 2006-03-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00082394
The ClinicalTrials.gov registry entry for NCT00082394 describes a study currently listed as completed, categorized as Phase 4. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which atazanavir is the first listed.
NCT00082394 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00082394 about?
NCT00082394 is a clinical study titled "A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV". The aim of this study was to assess whether TRIZIVIR, administered twice-daily was as safe, tolerable and efficacious as a combination of the drugs COMBIVIR administered twice-daily and atazanavir administered once daily. Over the course of 48 weeks, various parameters that measure safety, tolerabil...
What is the current status of trial NCT00082394?
This trial is currently completed. It is a Phase 4 study. The study started on 2004-04-26. Estimated completion is 2006-03-01.
What interventions are being tested in trial NCT00082394?
The interventions under investigation include: atazanavir (DRUG), Combivir (DRUG), Trizivir (DRUG).
Who is sponsoring clinical trial NCT00082394?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.